Fig. 5

Both CBX and Panx 1 siRNA treatment reduces the production of inflammatory factors in LPS-treated Schwann cells. A–C Pretreatment with CBX (100 μM) attenuated LPS-induced increases in IL-1β, IL-6, TNF-α mRNA. *p < 0.05, **p < 0.01, ***p < 0.001, vs. control group, ^#p < 0.05, ^##p < 0.01, vs. the LPS treatment alone group n = 3. D–F LPS-induced increases of IL-1β, IL-6, and TNF-α mRNA was inhibited by Panx 1- siRNA, but not in the Ctrl-siRNA group. *p < 0.05, **p < 0.01, vs. Ctrl-siRNA group n = 3–4. G, H, J, K Both CBX and Panx 1-siRNA treatment reduced LPS-induced protein expression of IL-1β and IL-6. *p < 0.05, ***p < 0.001, vs. control or the Ctrl-siRNA group, ^#p < 0.05, ^###p < 0.001, vs. LPS treatment alone group. n = 3. I, L Reduced IL-6 release was observed in the groups pretreated with CBX or Panx 1 siRNA, but not in the Ctrl-siRNA group. *p < 0.05, ***p < 0.001, vs. control or Ctrl-siRNA group, ^#p < 0.05, vs. LPS treatment alone group. n = 3. M Fold change of the expression of the selected cytokines and chemokines in different groups. *p < 0.05, vs. control, ^#p < 0.05 vs. LPS + Ctrl-siRNA treatment group n = 3. The significance between the groups was analyzed using Student’s t-test (for two groups), or one-way ANOVA followed by Tukey’s multiple comparison test (for ELISA results) or Dunnett’s test